ResearcherInstituto Nazionale Tumori Regina ElenaNo recent work listed
Luisa de Latouliere
Matched on ORCID iD 0000-0001-6444-9227; OpenAlex author ID A5025040615. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper
Papers 4
- The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/1878-0261.12847↗
- Diabetes promotes invasive pancreatic cancer by increasing systemic and tumour carbonyl stress in Kras G12D/+ mice. Co-author DOI 10.1186/s13046-020-01665-0↗
- The advanced glycation end-product Nϵ -carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes-associated risk and its prevent… Co-author DOI 10.1002/path.5072↗
- A bioluminescent mouse model of proliferation to highlight early stages of pancreatic cancer: A suitable tool for preclinical studies. Co-author DOI 10.1016/j.aanat.2015.11.010↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Giulia Piaggio · 4 shared papers, 2016–2021 · strength 0.36
- Paper The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal ad… DOI 10.1002/1878-0261.12847↗
- Paper Diabetes promotes invasive pancreatic cancer by increasing systemic and tumour carbonyl stress in Kras G12D/+ mice. DOI 10.1186/s13046-020-01665-0↗
- Paper The advanced glycation end-product Nϵ -carboxymethyllysine promotes progression of pancreatic cancer: implications for … DOI 10.1002/path.5072↗
- Stefano Menini · 3 shared papers, 2016–2020 · strength 0.24
- Paper Diabetes promotes invasive pancreatic cancer by increasing systemic and tumour carbonyl stress in Kras G12D/+ mice. DOI 10.1186/s13046-020-01665-0↗
- Paper The advanced glycation end-product Nϵ -carboxymethyllysine promotes progression of pancreatic cancer: implications for … DOI 10.1002/path.5072↗
- Paper A bioluminescent mouse model of proliferation to highlight early stages of pancreatic cancer: A suitable tool for precl… DOI 10.1016/j.aanat.2015.11.010↗
- Paola Cappello · 3 shared papers, 2016–2020 · strength 0.24
- Paper Diabetes promotes invasive pancreatic cancer by increasing systemic and tumour carbonyl stress in Kras G12D/+ mice. DOI 10.1186/s13046-020-01665-0↗
- Paper The advanced glycation end-product Nϵ -carboxymethyllysine promotes progression of pancreatic cancer: implications for … DOI 10.1002/path.5072↗
- Paper A bioluminescent mouse model of proliferation to highlight early stages of pancreatic cancer: A suitable tool for precl… DOI 10.1016/j.aanat.2015.11.010↗
- Francesco Novelli · 3 shared papers, 2016–2020 · strength 0.24
- Paper Diabetes promotes invasive pancreatic cancer by increasing systemic and tumour carbonyl stress in Kras G12D/+ mice. DOI 10.1186/s13046-020-01665-0↗
- Paper The advanced glycation end-product Nϵ -carboxymethyllysine promotes progression of pancreatic cancer: implications for … DOI 10.1002/path.5072↗
- Paper A bioluminescent mouse model of proliferation to highlight early stages of pancreatic cancer: A suitable tool for precl… DOI 10.1016/j.aanat.2015.11.010↗
- Giuseppe Pugliese · 3 shared papers, 2016–2020 · strength 0.24
- Paper Diabetes promotes invasive pancreatic cancer by increasing systemic and tumour carbonyl stress in Kras G12D/+ mice. DOI 10.1186/s13046-020-01665-0↗
- Paper The advanced glycation end-product Nϵ -carboxymethyllysine promotes progression of pancreatic cancer: implications for … DOI 10.1002/path.5072↗
- Paper A bioluminescent mouse model of proliferation to highlight early stages of pancreatic cancer: A suitable tool for precl… DOI 10.1016/j.aanat.2015.11.010↗
- Chiara Naro · 1 shared paper, 2021 · strength 0.12
- Valentina Panzeri · 1 shared paper, 2021 · strength 0.12
- Claudio Sette · 1 shared paper, 2021 · strength 0.12
- Gabriele Capurso · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.